DNLI · Denali Therapeutics Inc. · Debt
$20.22
+0.15 (+0.75%)
At close · Nov 9
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$3.22B
Shares
160.29M
Volume · Nov 9
156.99K
Avg daily vol (3M)
1.64M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Completed filing coverage through Mar 31, 2026Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2026-09-30 | USD 105,000 | 10-Q filed 2026-11-03 |
| Current operating lease liabilities | 2026-09-30 | USD 10,407,000 | 10-Q filed 2026-11-03 |
| Noncurrent finance lease liabilities | 2026-09-30 | USD 5,449,000 | 10-Q filed 2026-11-03 |
| Noncurrent operating lease liabilities | 2026-09-30 | USD 19,280,000 | 10-Q filed 2026-11-03 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1714899
CUSIP
24823R105
13F (30d)
125 filings
107 filers
Visit website
Investor relations